About the MPM Lab

The MPM lab is developing microsystems for the detection and characterization of personalised medicine.

We are currently focusing on:
1. The development of Integrated Biosensors for Disease Evaluation
- Bacterial targeted AIE photosensitizers synergistically promote chemotherapy for the treatment of inflammatory cancer. Chemical Engineering Journal 447, 137579.

- FlexiPulse: A machine-learning-enabled flexible pulse sensor for cardiovascular disease diagnostics, Cell Reports Physical Science 4.

- Thin and soft Ti3C2Tx MXene sponge structure for highly sensitive pressure sensor assisted by deep learning, Chemical Engineering Journal 485, 149659.

2. Improving patient treatment strategies and prognosis
- Label-free biosensor of phagocytosis for diagnosing bacterial infections. Biosens Bioelectron 191, 113412.

- A 6-gene panel as a signature to predict recovery from advanced heart failure using transcriptomic analysis. Genes & Diseases.

- AIEgen-deep: Deep learning of single AIEgen-imaging pattern for cancer cell discrimination and preclinical diagnosis, Biosensors and Bioelectronics, 116086.

3. How the microenvironment affects disease progression
- The effects of biofilms on tumor progression in a 3D cancer-biofilm microfluidic model. Biosens Bioelectron 180, 113113.

- Biofilm Potentiates Cancer-Promoting Effects of Tumor-Associated Macrophages in a 3D Multi-Faceted Tumor Model Small 453, Part 1, 28 p., 139595.

4. Integrated Microsystems
- A portable purification system for the rapid removal of microplastics from environmental samples. Chemical Engineering Journal 428, 132614.

- A deformability-based biochip for precise label-free stratification of metastatic subtypes using deep learning, Microsystems & Nanoengineering 9 (1), 120.

Integrated Microsystems

The MPM Lab emphasize on interdisciplinary research, to design and develop microsystems for biological issues. In many cases, existing methods to monitor disease may not always be sensitive enough for early-stage detection. We use techniques from biology and engineering to aid clinicians with new technology for direct clinical relevance.

Biosensors for treatment, monitoring

We develop microsystems which can act as relevant in vitro models for predicting treatment response and to monitor patient prognosis. Rapid screening allow doctors to quickly intervene and improve therapeutic strategies, or to guide the choice of therapy in patients.

Disease Microenvironment and Progression

Investigating the interplay of key players within the microenvironment has a strong potential impact to guide strategies in clinical trials, by revealing drug susceptibility or tolerance and allowing immediate intervention.

Point-of-care systems

Miniaturizing and lowering costs of medical instruments, Real-time health monitoring, Automated reliable therapeutic administrations

Microsystems for Personalised Medicine